{"id":1699,"date":"2021-01-20T13:44:57","date_gmt":"2021-01-20T13:44:57","guid":{"rendered":"https:\/\/tris.sambrownprojects.com\/tris-pharma-presents-positive-results-from-phase-3-study-of-amphetamine-extended-release-tablet-in-adults-with-adhd\/"},"modified":"2024-06-03T11:08:06","modified_gmt":"2024-06-03T10:08:06","slug":"tris-pharma-presents-positive-results-from-phase-3-study-of-amphetamine-extended-release-tablet-in-adults-with-adhd","status":"publish","type":"post","link":"https:\/\/www.trispharma.com\/tris-pharma-presents-positive-results-from-phase-3-study-of-amphetamine-extended-release-tablet-in-adults-with-adhd\/","title":{"rendered":"Tris Pharma Presents Positive Results from Phase 3 Study of Amphetamine Extended-Release Tablet in Adults with ADHD"},"content":{"rendered":"\r\n
Study met primary endpoint measure of sustained attention in adults with ADHD<\/strong><\/li>
Showed statistically significant improvement vs. placebo in mean PERMP-Total score measured from 0.5 hours to 14 hours post-dose <\/strong><\/li>
No new adverse reactions reported during the study<\/strong><\/li><\/ul>\r\n\r\n\r\n\r\n
MONMOUTH JUNCTION, NJ, January 20, 2021 \/ PRNewswire\/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, today announced that it presented data from a pivotal efficacy and safety study on its new amphetamine extended-release tablet at the virtual annual meeting of American Professional Society of ADHD and Related Disorders (APSARD), January 15 – 17, 2021.<\/p>\r\n\r\n\r\n\r\n
Results from the study, entitled \u201cRandomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of the Amphetamine Extended-Release Tablet in Adults with Attention-Deficit\/Hyperactivity Disorder,\u201d were reported during the annual APSARD meeting. The study was designed to evaluate the efficacy and safety of amphetamine extended-release tablets in adults aged 18-60 years with ADHD compared with placebo.<\/p>\r\n\r\n\r\n\r\n